Telogen effluvium
diseaseOn this page
Summary
Telogen effluvium (MONDO:0002153) is a disease and 17 clinical trials. Top therapeutic interventions include biotin and phenylephrine. A subtype of alopecia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 17
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | telogen effluvium |
| Mondo ID | MONDO:0002153 |
| DOID | DOID:1943 |
| ICD-10-CM | L65.0 |
| ICD-11 | 1188535025 |
| NCIT | C112200 |
| SNOMED CT | 39479004 |
| UMLS | C0263518 |
| MedGen | 537938 |
| GARD | 0023077 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of alopecia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unit › hair anomaly › alopecia › telogen effluvium
Related subtypes (25): alopecia, isolated, alopecia areata, chemotherapy-induced alopecia, alopecia mucinosa, atrichia with papular lesions, loose anagen syndrome, Satoyoshi syndrome, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, hereditary hypotrichosis with recurrent skin vesicles, alopecia antibody deficiency, pseudopelade of Brocq, frontal fibrosing alopecia, Quinquaud’s folliculitis decalvans, Graham Little-Piccardi-Lassueur syndrome, lichen planopilaris, hypotrichosis simplex, alopecia totalis, hypotrichosis simplex of the scalp, endocrine alopecia, alopecia universalis onychodystrophy vitiligo, central centrifugal cicatricial alopecia, ectodermal dysplasia alopecia preaxial polydactyly, Slti-Salem syndrome, microcephaly sparse hair intellectual disability seizures, alopecia universalis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 17.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03659201 | PHASE4 | COMPLETED | Efficacy and Safety of Neosil on Chronic Effluvium |
| NCT06648850 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth |
| NCT04880889 | PHASE3 | UNKNOWN | BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women. |
| NCT07484061 | Not specified | RECRUITING | Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists |
| NCT02548689 | Not specified | TERMINATED | PAI-1 Expression in Non-scarring Hair Loss |
| NCT03272750 | Not specified | COMPLETED | Evaluation of Tolerance and Trichological Efficacy of a Food Supplement |
| NCT04237402 | Not specified | COMPLETED | Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women |
| NCT04450589 | Not specified | COMPLETED | A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss |
| NCT04450602 | Not specified | COMPLETED | A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss |
| NCT04652232 | Not specified | COMPLETED | Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women |
| NCT04834102 | Not specified | UNKNOWN | COVID-19 Induced Telogen Effluvium |
| NCT06545552 | Not specified | COMPLETED | Efficacy and Safety of a Dietary Supplement on Hair Growth and Hair Health in Female With Acute Telogen Effluvium |
| NCT07111312 | Not specified | COMPLETED | Clinical Evaluation of a Nutraceutical Supplement (Olistic Women) for Hair Growth and Hair Loss in Human Volunteers |
| NCT07348120 | Not specified | COMPLETED | Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment |
| NCT07358403 | Not specified | COMPLETED | Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss |
| NCT07412587 | Not specified | COMPLETED | Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study |
| NCT07433933 | Not specified | COMPLETED | Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss. |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BIOTIN | 4 | 1 |
| PHENYLEPHRINE | 4 | 1 |
| CHEMBL4782949 | 0 | 1 |
Related Atlas pages
- Drugs: Biotin, Phenylephrine